June 26, 2024
A Delaware bankruptcy judge on Wednesday gave her blessing for pharmaceutical developer PhaseBio Pharmaceuticals Inc. to liquidate its assets and wind down after settlement agreements with creditors and a business partner cleared a path for it to exit Chapter 11 after roughly 19 months.
February 06, 2023
An Italian pharmaceutical company chosen to serve as a bidder-to-beat for a later-canceled Delaware Chapter 11 auction of drug research firm PhaseBio Pharmaceuticals still deserves a $2 million breakup fee based on the proposal's benefit to the estate, a bankruptcy judge ruled on Monday.
January 17, 2023
An Italian pharmaceutical company told a Delaware bankruptcy judge Tuesday that it is entitled to a $2 million fee for submitting an unsuccessful baseline bid for a bankrupt drug research firm even though the company chose a settlement instead of going through with the asset sale.